Jiménez-Lara A M, Clarke N, Altucci L, Gronemeyer H
Department of Cell Biology and Signal Transduction, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/CNRS/INSERM/ULP, BP 163, 67404 Illkirch, C. U. de Strasbourg, France.
Trends Mol Med. 2004 Oct;10(10):508-15. doi: 10.1016/j.molmed.2004.08.006.
Retinoic acid (RA) cures more than 75% of patients with acute promyelocytic leukemia (APL). Here, we review the various anti-cancer activities of retinoids and rexinoids, alone and in combination with other drugs, with emphasis on the RA-dependent induction of a cancer-cell-selective apoptosis signaling pathway to which multiple anti-cancer signals converge. These findings identify the TRAIL (tumor-necrosis-factor-related apoptosis-inducing ligand) pathway as a central cell-autonomous anti-cancer weapon that can act independently of the immune system.
维甲酸（RA）可治愈超过75%的急性早幼粒细胞白血病（APL）患者。在此，我们综述了类视黄醇和视黄酸X受体激动剂单独或与其他药物联合使用时的各种抗癌活性，重点关注依赖RA诱导的癌细胞选择性凋亡信号通路，多种抗癌信号汇聚于此。这些发现确定肿瘤坏死因子相关凋亡诱导配体（TRAIL）通路是一种核心的细胞自主抗癌武器，其作用可独立于免疫系统。
